We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+21.59%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.01B
AUM Growth
+$159M
Cap. Flow
-$108M
Cap. Flow %
-5.35%
Top 10 Hldgs %
68.56%
Holding
39
New
1
Increased
7
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$20.7M
2
VRDN icon
Viridian Therapeutics
VRDN
+$6.29M
3
CLDX icon
Celldex Therapeutics
CLDX
+$4.33M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$1.66M
5
MRUS
Merus
MRUS
+$1.31M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$38.5M
2
CRM icon
Salesforce
CRM
+$28.6M
3
BN icon
Brookfield
BN
+$18.4M
4
PCVX icon
Vaxcyte
PCVX
+$18M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.87%
2 Financials 10.69%
3 Technology 10.64%
4 Consumer Discretionary 2.64%
5 Communication Services 2.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Morningstar Total Stock Market ETF
VTI
$646B
$294M 14.61%
1,038,550
– –
TEM
2
Tempus AI
TEM
$7.48B
$231M 11.45%
4,074,419
– –
BN icon
3
Brookfield
BN
$102B
$186M 9.22%
5,236,845
-583,500
-10% -$18.4M
EWTX icon
4
Edgewise Therapeutics
EWTX
$4.28B
$148M 7.36%
5,549,900
-794,530
-13% -$15.8M
CORT icon
5
Corcept Therapeutics
CORT
$9.98B
$112M 5.54%
2,411,362
– –
ASML icon
6
ASML
ASML
$596B
$111M 5.52%
133,336
– –
CRM icon
7
Salesforce
CRM
$154B
$101M 5.01%
368,560
-111,600
-23% -$28.6M
PCVX icon
8
Vaxcyte
PCVX
$7.65B
$85.7M 4.26%
750,000
-200,000
-21% -$18M
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$6.56B
$58.5M 2.91%
1,500,000
– –
VRDN icon
10
Viridian Therapeutics
VRDN
$2.2B
$54.3M 2.69%
2,385,000
+385,000
+19% +$6.29M
BABA icon
11
Alibaba
BABA
$276B
$53.1M 2.64%
500,827
– –
INSM icon
12
Insmed
INSM
$22.4B
$52.9M 2.63%
724,666
-75,334
-9% -$5.56M
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.88B
$51.1M 2.54%
1,000,000
– –
CABO icon
14
Cable One
CABO
$237M
$41.4M 2.06%
118,403
– –
AVBP icon
15
ArriVent BioPharma
AVBP
$1.4B
$35.4M 1.76%
1,505,315
+5,315
+0.4% +$121K
MRUS
16
DELISTED
Merus
MRUS
$35M 1.74%
700,000
+25,000
+4% +$1.31M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.9B
$34.4M 1.71%
490,000
– –
CLDX icon
18
Celldex Therapeutics
CLDX
$2.94B
$32.8M 1.63%
963,663
+113,663
+13% +$4.33M
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$38.3B
$32.6M 1.62%
118,383
– –
PHVS icon
20
Pharvaris
PHVS
$2.28B
$31.9M 1.59%
1,725,000
– –
LNZA icon
21
LanzaTech
LNZA
$59.9M
$30.2M 1.5%
158,148
– –
BAM icon
22
Brookfield Asset Management
BAM
$75.6B
$29.7M 1.47%
627,207
– –
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
$28.5M 1.41%
1,544,000
– –
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$26.7M 1.33%
2,500,000
– –
RCKT icon
25
Rocket Pharmaceuticals
RCKT
$343M
$20.3M 1.01%
1,100,000
– –
1
2

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q3 2024 Portfolio in Review

As of Q3 2024, Novo Holdings A/S held 39 positions worth $2.01B, up 8.5% from $1.85B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Novo Holdings A/S withdrew a net $108M in Q3 2024, closing 2 positions and reducing 7 holdings. Its most notable exit was Apple, an estimated $38.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 53% a quarter earlier, followed by Financials and Technology.

Against the trend, Novo Holdings A/S opened a new position in Zenas BioPharma worth $19.5M.

  • Novo Holdings A/S's largest Q3 2024 buy was Zenas BioPharma: 1,150,000 shares worth $19.5M.
  • Novo Holdings A/S added most to Viridian Therapeutics in Q3 2024, an estimated $6.29M increase.
  • Novo Holdings A/S's biggest Q3 2024 reduction was Salesforce, cutting an estimated $28.6M.
  • Novo Holdings A/S fully exited Apple in Q3 2024, selling an estimated $38.5M.
  • Novo Holdings A/S's ten largest holdings make up 69% of its $2.01B portfolio in Q3 2024.
  • Novo Holdings A/S opened 1 new position and closed 2 in Q3 2024.
  • Novo Holdings A/S's portfolio value rose 8.5% quarter-over-quarter to $2.01B.

Based on Novo Holdings A/S's 13F filing for Q3 2024, filed 24 Oct 2024.